Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;26(5):329-339.
doi: 10.1097/PAP.0000000000000243.

A Comprehensive Review of Ovarian Serous Carcinoma

Yuichiro Hatano  1 , Kayoko Hatano  2 , Maho Tamada  1 , Ken-Ichirou Morishige  2 , Hiroyuki Tomita  1 , Hiroyuki Yanai  3 , Akira Hara  1
Affiliations
Review

A Comprehensive Review of Ovarian Serous Carcinoma

Yuichiro Hatano et al. Adv Anat Pathol. 2019 Sep.

Abstract

Although ovarian serous carcinoma is a well-studied human gynecologic malignancy, this high-grade tumor remains fatal. The main purpose of this review is to summarize the accumulated evidence on serous malignant tumors and to clarify the unresolved issues. We discuss the 8 dichotomies of serous carcinoma: high grade versus low grade, ovarian versus extraovarian primary, extrauterine versus uterine primary, sporadic versus hereditary, orthodox versus alternative histology, p53 overexpression versus complete absence of immunophenotype, TP53-mutated versus intact precursor, and therapy responsive versus refractory. In addition, we summarize the molecular classification of high-grade serous carcinoma. This review would lead readers to rapid and parallel developments in understanding high-grade serous carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Progress in ovarian serous carcinoma. APST indicates atypical proliferative serous tumor; CLOVAR, CLassification of OVARian cancer; CRS, chemotherapy response score; ESPs, early serous proliferations; FGT, female genital tract; FIGO, International Federation of Gynecology and Obstetrics; FT, fallopian tube; GOG, Gynecologic Oncology Group; HG, high-grade; HGSC, high-grade serous carcinoma; LG, low-grade; LGSC, low-grade serous carcinoma; MP, MicroPapillary variant; NI, noninvasive; PARP, Poly (ADP-Ribose) Polymerase; SBT, serous borderline tumor; SCOUT, Secretory Cell OUTgrowth; SEE-FIM, Sectioning and Extensively Examining the FIMbria; SET, solid, pseudo-endometrioid, and/or transitional cell carcinoma-like; STIC, serous tubal intraepithelial carcinoma; TCGA, The Cancer Genome Atlas; UICC, Union for International Cancer Control.
See this image and copyright information in PMC

References

    1. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of the Female Reproductive Organs. Lyon: WHO Press; 2014.
    1. Schiller W. Concept of a new classification of ovarian tumor. Surg Gynecol Obstet. 1940;70:773–782.
    1. Bassis ML. An embryologically derived classification of ovarian tumors. JAMA. 1960;174:1316–1319. - PubMed
    1. Gentile F, Junqueira AC. Ovarian Cancer UICC Monograph Series Volume 11. Heidelberg: Springer-Verlag, Berlin; 1968.
    1. Serov SF, Scully RE, Sobin LH. Histological Typing of Ovarian Tumours: International Histological Classification of Tumours No 9. Geneva: WHO; 1973.

MeSH terms

Substances